Engineers Gate Manager LP Takes $5.60 Million Position in Glaukos Corp (GKOS)

Engineers Gate Manager LP bought a new position in Glaukos Corp (NYSE:GKOS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 86,272 shares of the medical instruments supplier’s stock, valued at approximately $5,599,000. Engineers Gate Manager LP owned 0.25% of Glaukos as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GKOS. MetLife Investment Advisors LLC raised its holdings in shares of Glaukos by 13.5% during the second quarter. MetLife Investment Advisors LLC now owns 15,446 shares of the medical instruments supplier’s stock worth $628,000 after acquiring an additional 1,838 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Glaukos by 5.9% during the third quarter. Bank of Montreal Can now owns 39,000 shares of the medical instruments supplier’s stock worth $2,532,000 after acquiring an additional 2,190 shares in the last quarter. Great West Life Assurance Co. Can raised its holdings in shares of Glaukos by 112.0% during the second quarter. Great West Life Assurance Co. Can now owns 4,240 shares of the medical instruments supplier’s stock worth $172,000 after acquiring an additional 2,240 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Glaukos by 10.2% during the first quarter. Principal Financial Group Inc. now owns 29,787 shares of the medical instruments supplier’s stock worth $918,000 after acquiring an additional 2,746 shares in the last quarter. Finally, Artisan Partners Limited Partnership raised its holdings in shares of Glaukos by 0.7% during the second quarter. Artisan Partners Limited Partnership now owns 426,246 shares of the medical instruments supplier’s stock worth $17,323,000 after acquiring an additional 2,845 shares in the last quarter.

NYSE GKOS opened at $60.08 on Friday. Glaukos Corp has a fifty-two week low of $23.08 and a fifty-two week high of $70.91.

Glaukos (NYSE:GKOS) last posted its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.03). The company had revenue of $43.16 million for the quarter, compared to the consensus estimate of $40.51 million. Glaukos had a negative net margin of 3.49% and a negative return on equity of 4.11%. Glaukos’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.10) earnings per share. As a group, research analysts predict that Glaukos Corp will post -0.55 earnings per share for the current year.

GKOS has been the subject of several recent research reports. ValuEngine upgraded Glaukos from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 29th. BMO Capital Markets increased their price objective on Glaukos from $59.00 to $62.00 and gave the stock a “market perform” rating in a report on Thursday, August 30th. Piper Jaffray Companies increased their price objective on Glaukos to $73.00 and gave the stock an “overweight” rating in a report on Friday, August 31st. JPMorgan Chase & Co. upgraded Glaukos from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $42.00 to $75.00 in a report on Wednesday, August 29th. Finally, Stephens restated an “overweight” rating and set a $57.00 target price on shares of Glaukos in a report on Wednesday, August 29th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Glaukos presently has an average rating of “Buy” and a consensus price target of $58.20.

In other news, Director Gilbert H. Kliman sold 502,760 shares of Glaukos stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $60.39, for a total value of $30,361,676.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas William Burns sold 150,000 shares of Glaukos stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of $38.78, for a total value of $5,817,000.00. The disclosure for this sale can be found here. Insiders own 11.60% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Featured Article: Dollar Cost Averaging

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply